Search Results
Oct 07, 2025, 06:01 ET Welding Consumables Market Set for Steady Growth; APAC Leads, MEA Fastest Growing, Says Mordor Intelligence
Systems GYS S.A.S. Nippon Steel Welding & Engineering Oerlikon (CD&R-owned) Daihen Corporation Great Welding Ltd. Kiswel Co. Ltd.
More news about: Mordor Intelligence Private Limited
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
intravenously, that targets the CD20 protein expressed on lymphoma and leukemia cells. Unlike traditional CD20 antibodies, it binds specifically to Type 2 CD20, resulting in stronger antibody-dependent cytotoxicity and more potent direct cytotoxic activity. Once attached to CD20, obinutuzumab induces B-cell
More news about: DelveInsight Business Research, LLP
Oct 06, 2025, 12:12 ET RUSH ANNOUNCE 2026 TOUR
available in five distinct configurations, including the (1) Super Deluxe Edition, (2) RUSH Store Exclusive Super Deluxe Edition, (3) 7-LP Deluxe Edition, (4) 4-CD Deluxe Edition, and (5) Digital Edition. It represents breadth of their discography, beginning with the first-ever reissue of their 1973 debut single
More news about: Rock and Roll Hall of Fame
Oct 06, 2025, 09:46 ET Allyable's The First AI-Powered Digital Accessibility Platform Now Available in the AWS Marketplace
& workflows throughout a digital product's entire life cycle Robust APIs & connectors for deep integrations with CI/CD & CMS systems Concierge support & AI automation that ensure teams can self-execute and implement accessibility successfully
More news about: Allyable™
Oct 06, 2025, 09:00 ET AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
years of age and older with spasticity To treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older To treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids
More news about: AbbVie
Oct 06, 2025, 08:18 ET Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
initial manifestations of CD. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge with most affected children developing life-threatening complications by approximately 10 years of age. Currently, there are no cures for CD, and only palliative
More news about: Myrtelle, Inc
Oct 06, 2025, 08:00 ET Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming
Proof-of-mechanism: Paired biopsies confirmed CAR+ immune cells infiltrating tumors, with immune remodeling and CD8 T cell recruitment. Safety and repeat dosing: Over 200 doses delivered with a consistent, manageable
More news about: CREATE Medicines, Inc.
Oct 03, 2025, 10:00 ET HanchorBio Announces Acceptance of HCB301 Abstract for Poster Presentation at SITC 2025 Annual Meeting
blockade of PD-L1 and TGF-β signaling, Robust phagocytosis of CD47+ tumor cells in vitro with minimal red blood cell binding, suggesting an improved hematologic safety profile compared to CD47-targeting analogs, and In vivo efficacy comparable to a triple-agent
More news about: HanchorBio Inc.
Oct 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Oct 03, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
being held October 5-9 in Honolulu, HI. ND0612 is being evaluated as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD).
More news about: Mitsubishi Tanabe Pharma America
Oct 02, 2025, 09:31 ET CD Valet's September CD Rate Analysis Reveals Accelerated Decline in CD Rates Following Federal Reserve Action
In its monthly Ratewatcher report, CD Valet analyzes its digital marketplace which includes all CDs offered by financial institutions that publish their CD rates online. This analysis is based on CD Valet's comprehensive data which includes more than 38,000 retail CD rates, representing nearly 5,000 banks
More news about: CD Valet
Oct 02, 2025, 09:01 ET Taylor Swift's 'The Life of a Showgirl' Arrives Oct. 3: Here's How to Shop Target's Exclusives and Midnight Releases
Showgirl: It's Frightening" CD with poster (Target exclusive)"The Life of a Showgirl: It's Rapturous" CD with poster (Target exclusive)"The Life of a Showgirl: It's Beautiful" CD with poster (Target exclusive)"The Life of a Showgirl: Sweat and Vanilla Perfume" CD with poster (standard)"The
More news about: Target Corporation
Oct 02, 2025, 08:00 ET Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI
CD19 binder, which was developed by the University of Pennsylvania (Penn) under a sponsored research agreement between Penn and Verismo and exclusively
More news about: Verismo Therapeutics
Oct 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Oct 01, 2025, 02:00 ET Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
high-risk biochemical recurrence. First clinical data from Astellas' investigational CLDN18.2-targeted, next-generation bispecific CD3 T cell engager ASP2138, both as a monotherapy and in combination with standard of care therapy.
More news about: Astellas Pharma Inc.
Sep 30, 2025, 09:32 ET Harness Report Reveals AI Velocity Paradox: Productivity Gains Undone by Downstream Bottlenecks
Automation is lagging: Only 6% describe their continuous delivery process as fully automated – yet moving from low to moderate CD automation more than doubles the likelihood of realizing velocity gains as it rises from 26% to 57%.
More news about: Harness
Sep 30, 2025, 08:00 ET AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
antileukemia activity of PVEK when administered to subjects with CD123+ hematologic malignancies (including subjects with BPDCN, AML, and others). About Pivekimab Sunirine (PVEK)PVEK is a CD123-targeting ADC in clinical development for hematological
More news about: AbbVie
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory
More news about: Johnson & Johnson
Sep 29, 2025, 08:00 ET BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Sep 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Sep 26, 2025, 08:30 ET Grammy® Winner Charlie Porter Hides $10,000 Treasure Hunt Inside New Jazz Album
the $10,000 prize (contestants must provide proof of their solves as described in the Official Rules).Study the CD artwork for subtle hints to the clues.Availability:Cipher is released today, September 26,
More news about: Charlie Porter
Sep 26, 2025, 08:02 ET Breakout Singer-Songwriter Sydney Irving Signs Worldwide Record Deal with DEKO Entertainment / Warner Music Group-ADA
PURCHASE THE CD OF UNFASHIONED CREATURES BY SYDNEY IRVING "We are thrilled to be working with our good friend
More news about: PILATO ENTERTAINMENT MARKETING & MEDIA LLC
Sep 25, 2025, 18:39 ET Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
donanemab TRAILBLAZER-ALZ study findings. Neurol Clin Pract. 2023;13(2):e200127. doi:10.1212/CPJ.0000000000200127Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239.Ross
More news about: Eli Lilly and Company
Sep 25, 2025, 17:31 ET TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
binds to death receptor 3 (DR3), also referred to as tumor necrosis factor receptor superfamily member 25 (TNFRSF25), which is mainly expressed on CD4+ and CD8+ effector T cells as well as natural killer cells. This binding activates downstream signaling cascades that drive T cell proliferation and stimulate
More news about: DelveInsight Business Research, LLP
Sep 25, 2025, 14:14 ET Axon Therapies Raises $32M in Oversubscribed Series A to Transform Heart Failure Treatment
co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation by existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.
More news about: Axon Therapies